| 前收市價 | 0.0500 |
| 開市 | 0.0500 |
| 買盤 | 0.0000 |
| 賣出價 | 1.0000 |
| 拍板 | 25.00 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 0.0500 - 0.0600 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 175 |
BenzingaElanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy
On Thursday, the FDA approved Elanco Animal Health Incorporated’s (NYSE:ELAN) Zenrelia, a once-daily oral JAK inhibitor for the control of pruritus (itching) associated with allergic dermatitis and atopic dermatitis in dogs at least 12 months of age. Approximately 17 million dogs suffer from allergic skin disease, including atopic dermatitis, food allergies, or flea sensitivity. Also Read: Elanco Animal Health Shares Sink On Unexpected Label Update For Canine Dermatology Drug. Elanco conducted a
ReutersUS FDA approves Elanco's skin disease treatment for dogs
(Reuters) -The U.S. Food and Drug Administration has approved Elanco Animal Health's skin disease treatment for dogs, the health regulator's website showed on Thursday, sending the company's shares up 2% in afternoon trade. The oral drug, Zenrelia, aims to control pruritus, or itching, associated with allergic dermatitis and to control atopic dermatitis in dogs that are at least 12 months old. Elanco considers Zenrelia as one of its potential blockbusters.
Motley FoolElanco Animal Health (ELAN) Q2 2024 Earnings Call Transcript
ELAN earnings call for the period ending June 30, 2024.
